BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev 2016;15:955-63. [PMID: 27490204 DOI: 10.1016/j.autrev.2016.07.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
2 Morvillo C, Vinci K, Hedenschoug L, Mancini L, Mize C, Tugg K, Stein S. Risks and Safety of Advanced Therapies and Biologics in Inflammatory Bowel Disease: A Review for Nurses. Gastroenterology Nursing 2020;43:E159-71. [DOI: 10.1097/sga.0000000000000523] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol 2017;3:21-5. [PMID: 28492050 DOI: 10.1016/j.ijwd.2016.12.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
4 Sousa P, Allez M. Complications of biologics in inflammatory bowel disease. Curr Opin Gastroenterol. 2015;31:296-302. [PMID: 26039721 DOI: 10.1097/mog.0000000000000191] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. World J Rheumatol 2015; 5(2): 50-58 [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
6 Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol 2018;113:1678-88. [PMID: 30022113 DOI: 10.1038/s41395-018-0202-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
7 Shannahan SE, Erlich JM, Peppercorn MA. Insights into the treatment of inflammatory bowel disease in pregnancy. Therap Adv Gastroenterol 2019;12:1756284819852231. [PMID: 31191713 DOI: 10.1177/1756284819852231] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Golic M, Luft FC, Dechend R. Tumor Necrosis Factor-α, Uterine Natural Killer Cells, and Pregnancy. Hypertension 2016;68:1108-9. [DOI: 10.1161/hypertensionaha.116.08028] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Ince-Askan H, Dolhain RJ. Pregnancy and rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:580-96. [PMID: 26697768 DOI: 10.1016/j.berh.2015.07.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
10 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, Strubbe B, Van Hootegem A, Van Moerkercke W, Vermeire S, Ferrante M; Belgian IBD Research and Development group (BIRD). Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis 2019;13:12-8. [PMID: 30281093 DOI: 10.1093/ecco-jcc/jjy142] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
12 田玲玲, 刘丽娜. 溃疡性结肠炎治疗的现代观点. 世界华人消化杂志 2016; 24(7): 1054-1063 [DOI: 10.11569/wcjd.v24.i7.1054] [Reference Citation Analysis]
13 Rosales Santillan M, Morss PC, Porter ML, Kimball AB. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 2020;20:621-33. [PMID: 32077334 DOI: 10.1080/14712598.2020.1732918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
14 de Paula-Silva M, Barrios BE, Macció-Maretto L, Sena AA, Farsky SH, Correa SG, Oliani SM. Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis. Biochem Pharmacol 2016;115:104-13. [PMID: 27343762 DOI: 10.1016/j.bcp.2016.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
15 Grgić D, Čuković Čavka S, Elveđi Gašparović V, Turk N, Brinar M, Marušić Z, Krznarić Ž. Pregnancy-Onset Acute Severe Colitis after in vitro Fertilization Embryo Transfer. Case Rep Gastroenterol 2020;14:477-82. [PMID: 33173464 DOI: 10.1159/000509502] [Reference Citation Analysis]
16 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
17 Mekinian A, Cohen J, Alijotas-reig J, Carbillon L, Nicaise-roland P, Kayem G, Daraï E, Fain O, Bornes M. Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? Am J Reprod Immunol 2016;76:8-28. [DOI: 10.1111/aji.12493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 11.4] [Reference Citation Analysis]
18 Ali SB, Jeelall Y, Pennell CE, Hart R, Mclean-tooke A, Lucas M. The role of immunological testing and intervention in reproductive medicine: A fertile collaboration? Am J Reprod Immunol 2018;79:e12784. [DOI: 10.1111/aji.12784] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
19 Woon EV, Day A, Bracewell-Milnes T, Male V, Johnson M. Immunotherapy to improve pregnancy outcome in women with abnormal natural killer cell levels/activity and recurrent miscarriage or implantation failure: A systematic review and meta-analysis. J Reprod Immunol 2020;142:103189. [PMID: 32889304 DOI: 10.1016/j.jri.2020.103189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
20 Balbi GGM, Domingues V, Balbi GGM, De Jesús GR, Levy RA. Use of synthetic and biologic DMARDs during pregnancy. Expert Rev Clin Immunol 2019;15:27-39. [PMID: 30365902 DOI: 10.1080/1744666X.2019.1541739] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Ma C. To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00581-4. [PMID: 34058414 DOI: 10.1016/j.cgh.2021.05.043] [Reference Citation Analysis]
22 Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
23 Esteve-Solé A, Deyà-Martínez À, Teixidó I, Ricart E, Gompertz M, Torradeflot M, de Moner N, Gonzalez EA, Plaza-Martin AM, Yagüe J, Juan M, Alsina L. Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy. Front Immunol 2017;8:1123. [PMID: 28983301 DOI: 10.3389/fimmu.2017.01123] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
24 Carnovale C, Parisi F, Battini V, Zavatta A, Cheli S, Cattaneo D, Gringeri M, Mosini G, Guarnieri G, Cammarata G, Cetin I. The use of biological agents in pregnant women affected by autoimmune disorders: Why we need more research of this neglected area. Pharmacol Res 2021;171:105786. [PMID: 34314858 DOI: 10.1016/j.phrs.2021.105786] [Reference Citation Analysis]